A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Sponsor
Eisai

Protocol Number
E7080-G000-307

To Learn More Call
201-510-0910